MKI67 and neoplasm: In the PLC/PRF/5 xenograft model, Ki67 staining demonstrated that Lenvatinib treatment was most effective in the PLC/PRF/5 OE-GSDME group, where it significantly inhibited tumor proliferation (Figure 6e).